Actualising the power of antibody-drug conjugates as cancer therapeutics
European Pharmaceutical Review
AUGUST 24, 2022
ANTIBODY-DRUG conjugates (ADCs) are therapeutic molecules designed as highly targeted medicines with the promise of changing the way we treat cancer and other diseases. Early ADC developments centred on using cytotoxins with the highest potency together with limited linker designs. cancer agent or disease-relevant toxin.
Let's personalize your content